189 related articles for article (PubMed ID: 30794613)
1. Autophagic flux modulation by Wnt/β-catenin pathway inhibition in hepatocellular carcinoma.
Turcios L; Chacon E; Garcia C; Eman P; Cornea V; Jiang J; Spear B; Liu C; Watt DS; Marti F; Gedaly R
PLoS One; 2019; 14(2):e0212538. PubMed ID: 30794613
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function.
Turcios L; Vilchez V; Acosta LF; Poyil P; Butterfield DA; Mitov M; Marti F; Gedaly R
Dig Liver Dis; 2017 Jun; 49(6):697-704. PubMed ID: 28179093
[TBL] [Abstract][Full Text] [Related]
3. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.
Galuppo R; Maynard E; Shah M; Daily MF; Chen C; Spear BT; Gedaly R
Anticancer Res; 2014 Apr; 34(4):1709-13. PubMed ID: 24692700
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Wnt/β-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535.
Gedaly R; Galuppo R; Daily MF; Shah M; Maynard E; Chen C; Zhang X; Esser KA; Cohen DA; Evers BM; Jiang J; Spear BT
PLoS One; 2014; 9(6):e99272. PubMed ID: 24940873
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
[TBL] [Abstract][Full Text] [Related]
7. The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells.
Wang J; Wei H; Huang Y; Chen D; Zeng G; Lian Y; Huang Y
Aging (Albany NY); 2019 Aug; 11(15):5769-5785. PubMed ID: 31409760
[TBL] [Abstract][Full Text] [Related]
8. Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways.
Cheng Z; Yuan X; Qu Y; Li X; Wu G; Li C; Zu X; Yang N; Ke X; Zhou J; Xie N; Xu X; Liu S; Shen Y; Li H; Zhang W
Cancer Lett; 2017 Sep; 403():195-205. PubMed ID: 28645563
[TBL] [Abstract][Full Text] [Related]
9. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
10. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
Liu Y; Ye X; Zhang JB; Ouyang H; Shen Z; Wu Y; Wang W; Wu J; Tao S; Yang X; Qiao K; Zhang J; Liu J; Fu Q; Xie Y
Oncogene; 2015 Oct; 34(44):5524-35. PubMed ID: 25684142
[TBL] [Abstract][Full Text] [Related]
11. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
Leung HW; Leung CON; Lau EY; Chung KPS; Mok EH; Lei MML; Leung RWH; Tong M; Keng VW; Ma C; Zhao Q; Ng IOL; Ma S; Lee TK
Cancer Res; 2021 Jun; 81(12):3229-3240. PubMed ID: 33903122
[TBL] [Abstract][Full Text] [Related]
12. Repression of WT1-Mediated LEF1 Transcription by Mangiferin Governs β-Catenin-Independent Wnt Signalling Inactivation in Hepatocellular Carcinoma.
Tan HY; Wang N; Li S; Hong M; Guo W; Man K; Cheng CS; Chen Z; Feng Y
Cell Physiol Biochem; 2018; 47(5):1819-1834. PubMed ID: 29953980
[TBL] [Abstract][Full Text] [Related]
13. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
[TBL] [Abstract][Full Text] [Related]
14. Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells.
Wei W; Chua MS; Grepper S; So SK
Mol Cancer; 2009 Sep; 8():76. PubMed ID: 19778454
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β‑catenin pathway in xenograft models of hepatocellular carcinoma.
Huynh H; Ong R; Goh KY; Lee LY; Puehler F; Scholz A; Politz O; Mumberg D; Ziegelbauer K
Int J Oncol; 2019 Mar; 54(3):1123-1133. PubMed ID: 30747223
[TBL] [Abstract][Full Text] [Related]
16. Autophagy promotes metastasis and glycolysis by upregulating MCT1 expression and Wnt/β-catenin signaling pathway activation in hepatocellular carcinoma cells.
Fan Q; Yang L; Zhang X; Ma Y; Li Y; Dong L; Zong Z; Hua X; Su D; Li H; Liu J
J Exp Clin Cancer Res; 2018 Jan; 37(1):9. PubMed ID: 29351758
[TBL] [Abstract][Full Text] [Related]
17. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
Lachenmayer A; Alsinet C; Savic R; Cabellos L; Toffanin S; Hoshida Y; Villanueva A; Minguez B; Newell P; Tsai HW; Barretina J; Thung S; Ward SC; Bruix J; Mazzaferro V; Schwartz M; Friedman SL; Llovet JM
Clin Cancer Res; 2012 Sep; 18(18):4997-5007. PubMed ID: 22811581
[TBL] [Abstract][Full Text] [Related]
18. Urolithin B suppresses tumor growth in hepatocellular carcinoma through inducing the inactivation of Wnt/β-catenin signaling.
Lv MY; Shi CJ; Pan FF; Shao J; Feng L; Chen G; Ou C; Zhang JF; Fu WM
J Cell Biochem; 2019 Oct; 120(10):17273-17282. PubMed ID: 31218741
[TBL] [Abstract][Full Text] [Related]
19. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
20. FH535 suppresses the proliferation and motility of hepatocellular carcinoma cells.
Tomizawa M; Shinozaki F; Motoyoshi Y; Sugiyama T; Yamamoto S; Ishige N
Int J Oncol; 2016 Jan; 48(1):110-4. PubMed ID: 26530115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
